27306834|t|Naïve CD8(+) T cell derived tumor - specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment
27306834|a|Despite of the potential implications for cancer immunotherapy, conventional approaches using in vitro expanded CD8(+) T cells have suboptimal outcomes, mostly due to loss of functionality from cellular exhaustion. We therefore investigated the phenotypic and functional differences among in vitro activated CD8(+) T cells of three different sources, namely naïve (NTeff), memory (MTeff) and tumor-infiltrating lymphocytes (TILeff) from human and mice, to better understand mechanisms behind potent effector functions and potential for overcoming current limitations. In line with the greater proliferation activity and longer telomere lengths of NTeff populations, cells of naïve origin exhibited significantly less amounts of T cell exhaustion markers than those of MTeff and TILeff, and moreover, acquired distinct expression patterns of memory-promoting transcription factors, T-bet and Eomes, induced in a rapid and sustainable manner. NTeff cells appeared to have lower expression of Foxp1 and were refractory to apoptosis upon TGF-β conditioning, implying better survival potential and resistance to tumor - induced immune suppression. Of CD8(+) T cell pools activated to tumor - specific CTLs, naïve cell generated effectors possessed the most potent cytotoxic activity, validating implications for use in rational design of adoptive immunotherapy.
27306834	0	5	Naïve	T025	C3641721
27306834	6	19	CD8(+) T cell	T025	C0242629
27306834	28	33	tumor	T191	C0027651
27306834	36	44	specific	T080	C0205369
27306834	45	64	cytotoxic effectors	T025	C3641722
27306834	80	86	remedy	T077	C1880198
27306834	102	107	TGF-β	T116,T123	C0040690
27306834	108	125	immunosuppression	T047	C4048329
27306834	133	155	tumor microenvironment	T070	C2936626
27306834	198	218	cancer immunotherapy	T061	C0278348
27306834	220	232	conventional	T080	C0439858
27306834	233	243	approaches	T169	C1292724
27306834	250	258	in vitro	T080	C1533691
27306834	259	267	expanded	T082	C0205229
27306834	268	282	CD8(+) T cells	T025	C0242629
27306834	288	298	suboptimal	T080	C2984009
27306834	299	307	outcomes	T080	C0085415
27306834	323	327	loss	T081	C1517945
27306834	331	344	functionality	T169	C0542341
27306834	350	358	cellular	T025	C0007634
27306834	359	369	exhaustion	UnknownType	C0678684
27306834	401	411	phenotypic	T032	C0031437
27306834	416	426	functional	T169	C0205245
27306834	427	438	differences	T080	C1705242
27306834	445	453	in vitro	T080	C1533691
27306834	454	463	activated	T052	C1879547
27306834	464	478	CD8(+) T cells	T025	C0242629
27306834	498	505	sources	T033	C0449416
27306834	514	519	naïve	T025	C3641721
27306834	521	526	NTeff	T025	C3641721
27306834	529	535	memory	T025	C0682639
27306834	537	542	MTeff	T025	C0682639
27306834	548	578	tumor-infiltrating lymphocytes	T025	C0079722
27306834	580	586	TILeff	T025	C0079722
27306834	593	598	human	T016	C0086418
27306834	603	607	mice	T015	C0025929
27306834	630	640	mechanisms	T169	C0441712
27306834	655	663	effector	T025	C3641722
27306834	664	673	functions	T169	C0542341
27306834	711	722	limitations	T169	C0449295
27306834	749	762	proliferation	T043	C0596873
27306834	763	771	activity	T052	C0441655
27306834	783	791	telomere	T026	C0085187
27306834	792	799	lengths	T081	C1444754
27306834	803	820	NTeff populations	T025	C3641721
27306834	822	827	cells	T025	C0007634
27306834	831	843	naïve origin	T079	C0439659
27306834	884	890	T cell	T025	C0039194
27306834	891	901	exhaustion	UnknownType	C0678684
27306834	902	909	markers	T201	C0005516
27306834	924	929	MTeff	T025	C0682639
27306834	934	940	TILeff	T025	C0079722
27306834	974	993	expression patterns	T045	C1171362
27306834	997	1035	memory-promoting transcription factors	T116,T123	C0040648
27306834	1037	1042	T-bet	T116	C0913648
27306834	1047	1052	Eomes	T116,T123	C1454790
27306834	1054	1061	induced	T169	C0205263
27306834	1067	1072	rapid	T080	C0456962
27306834	1077	1088	sustainable	T169	C0443318
27306834	1089	1095	manner	T169	C0205245
27306834	1097	1108	NTeff cells	T025	C3641721
27306834	1132	1142	expression	T045	C1171362
27306834	1146	1151	Foxp1	T116	C3273485
27306834	1175	1184	apoptosis	T043	C0162638
27306834	1190	1195	TGF-β	T116,T123	C0040690
27306834	1196	1208	conditioning	T169	C0205245
27306834	1226	1234	survival	T043	C0007620
27306834	1235	1244	potential	T080	C3245505
27306834	1249	1259	resistance	T169	C4281815
27306834	1263	1268	tumor	T191	C0027651
27306834	1271	1278	induced	T169	C0205263
27306834	1279	1297	immune suppression	T047	C4048329
27306834	1302	1315	CD8(+) T cell	T025	C0242629
27306834	1322	1331	activated	T052	C1879547
27306834	1335	1340	tumor	T191	C0027651
27306834	1343	1351	specific	T080	C0205369
27306834	1352	1356	CTLs	T025	C0039195
27306834	1358	1368	naïve cell	T025	C3641721
27306834	1369	1378	generated	T052	C3146294
27306834	1379	1388	effectors	T025	C3641722
27306834	1415	1433	cytotoxic activity	T033	C0243095
27306834	1479	1485	design	T052	C1707689
27306834	1489	1511	adoptive immunotherapy	T061	C0079613